Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy

Key Points

• Gastrointestinal outcomes improve with elexacaftor/tezacaftor/ivacaftor treatment, particularly in fat malabsorption.
• Key evidence shows fat malabsorption reduced by 30% in treated pediatric participants.
• Assessment of gastrointestinal function included inflammation and pancreatic health, highlighting significant gains.
• Findings support the need for comprehensive care in cystic fibrosis, aiming for better overall health in children.